Peliosis Hepatis

A vascular disease of the LIVER characterized by the occurrence of multiple blood-filled CYSTS or cavities. The cysts are lined with ENDOTHELIAL CELLS; the cavities lined with hepatic parenchymal cells (HEPATOCYTES). Peliosis hepatis has been associated with use of anabolic steroids (ANABOLIC AGENTS) and certain drugs.

Also Known As:

Networked: 99 relevant articles (1 outcomes, 1 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1.	Hyperplasia
2.	Neoplasms (Cancer)
3.	Liver Diseases (Liver Disease)
4.	Fibrosis (Cirrhosis)
5.	Infection

Experts

1.	Koea, Jonathan B: 1 article (10/2015)
2.	Aldameh, Ali: 1 article (10/2015)
3.	Srinivasa, Sanket: 1 article (10/2015)
4.	Lee, Wai G: 1 article (10/2015)
5.	Kubota, Mitsuru: 1 article (05/2015)
6.	Sakaguchi, Keita: 1 article (05/2015)
7.	Hagiwara, Shin-ichiro: 1 article (05/2015)
8.	Kagimoto, Seiichi: 1 article (05/2015)
9.	Hiwatari, Erika: 1 article (05/2015)
10.	Kishimoto, Hiroshi: 1 article (05/2015)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Peliosis Hepatis:

1.	Erythromycin (Erycette)FDA LinkGeneric 05/01/1995 - "We report a case of regressive peliosis hepatis, which occurred in a 55 year-old woman with diffuse intestinal lymphomatous polyposis in remission after treatment with chemotherapy and radiotherapy, and which was cleared after one month treatment with erythromycin. "
2.	SteroidsIBA 01/01/1994 - "This report concerns a 27-yr-old bodybuilder with peliosis hepatis, which developed after chronic intermittent use of anabolic steroids." 12/01/1992 - "The possible role of steroids and a possible relationship to the pathogenesis of peliosis hepatis is discussed." 01/01/1988 - "The changes were different from peliosis hepatis described in association with the taking of androgenic-anabolic steroids." 09/01/1985 - "Peliosis hepatis is an uncommon vascular lesion of unknown etiology, and its occurrence has been linked frequently to therapy with androgenic-anabolic steroids. " 09/08/1978 - "Peliosis hepatis should be considered in the differential diagnosis of hepatic disease in patients with hematologic disorders, especially if treatment has included androgenic-anabolic steroids."
3.	Oral ContraceptivesIBA 01/01/2013 - "The use of oral contraceptives for several years or the recent pregnancy may have been the cause of peliosis hepatis in this patient. " 11/01/2004 - "We report a patient who developed peliosis hepatis while taking oral contraceptives. " 05/01/1996 - " The authors report the case of a patient who developed peliosis hepatis while taking oral contraceptives. " 05/01/1988 - "The present report concerns a 43-yr-old woman with generalized peliosis hepatis that developed during long-term use of oral contraceptives. " 12/01/1982 - "Peliosis hepatis may be reversible when oral contraceptives are discontinued."
4.	Oxymetholone (Anadrol)FDA Link 02/01/1979 - "Peliosis hepatis due to oxymetholone--a clinically benign disorder." 07/21/1978 - "Peliosis hepatis associated with administration of oxymetholone." 05/04/1974 - "Letter: Peliosis hepatis after long-term administration of oxymetholone." 08/01/1980 - "It is suggested that damage to sinusoidal endothelium, with impairment of its ability to maintain sinusoidal collagenous reticulin, is a mechanism by which oxymetholone can cause peliosis hepatis in these patients." 08/01/1977 - "Peliosis hepatis was encountered in 12 patients treated with high-dose oxymetholone or fluoxymesterone therapy. "
5.	Estrogens (Estrogen)FDA Link 06/14/2006 - "Peliosis hepatis is a rare condition characterized by dilatation of hepatic sinusoids and blood-filled spaces in the liver mainly observed in subjects exposed to toxic substances or estrogens, which is frequently asymptomatic. " 01/01/2001 - "Estrogens can be responsible for the development of vascular disorders described as peliosis hepatis. " 01/01/2001 - "Peliosis hepatis has been described as a rare consequence of taking estrogens and contraceptive. " 01/01/2001 - "The primary estrogen-induced vascular disorders are peliosis hepatis and vasculitis. " 09/01/2005 - "The authors review the etiology, diagnosis, complications, treatment and potential role of estrogen/progesterone supplementation as an etiological factor, in peliosis hepatis."
6.	Azathioprine (Imuran)FDA LinkGeneric 09/14/2007 - "Azathioprine-induced peliosis hepatis is thought to be idiosyncratic in humans. " 06/10/2002 - "A case of peliosis hepatis in a 64-year-old woman treated with azathioprine because of a lung transplantation is described. " 01/01/1990 - "Up to now, azathioprine had been held responsible for peliosis hepatis only in renal transplant recipients." 09/14/2007 - "We describe a patient with Crohn's disease, treated with azathioprine, who developed peliosis hepatis after three epsiodes of alcohol binging. " 09/14/2007 - "Alcohol binging causes peliosis hepatis during azathioprine therapy in Crohn's disease."
7.	Cyclosporine (Ciclosporin)FDA LinkGeneric 01/01/1994 - "This suggests that cases of peliosis hepatis and nodular transformation which appear after renal transplantation are associated with immunosuppressants, and that cyclosporin treatment may also affect the morphogenesis of nodular transformation." 04/15/1998 - "Bacillary peliosis hepatis is an uncommon but well recognized disease due to disseminated Bartonella infections occurring predominantly in immunocompromised individuals infected with human immunodeficiency virus, type 1. A similar condition in the absence of Bartonella infection when described in organ transplant patients was felt to be secondary to azathioprine and/or cyclosporine. " 06/10/2002 - "Besides azathioprine, the patient was treated with cyclosporine and prednisolone, but none of these drugs are known to be responsible for the development of peliosis hepatis. "
8.	Fluoxymesterone (Halotestin)FDA Link 10/15/1960 - "Peliosis hepatis after administration of fluoxymesterone." 08/01/1977 - "Peliosis hepatis was encountered in 12 patients treated with high-dose oxymetholone or fluoxymesterone therapy. " 09/01/1985 - "Documented here is an unusual case of pulmonary peliosis, associated with peliosis hepatis and peliosis of the spleen, in a 40-year-old man who had Fanconi's anemia and who received long-term therapy with fluoxymesterone and methyltestosterone. "
9.	Contraceptive Agents (Contraceptives)IBA 09/18/1978 - " Caught at an early stage, peliosis hepatis can be reversed if the patient discontinues the use of contraceptives. " 01/01/2000 - "Peliosis hepatis is pathognomonic for treatment with contraceptives and for severe chronic diseases, as tuberculosis or tumour. " 08/01/1984 - "Peliosis hepatis is pathologically characterized by blood-filled cystic spaces in the liver associated with the administration of anabolic androgenic steroids or oral contraceptive agents, particularly those with large components of estrogen. "
10.	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 06/19/2001 - "Moreover, this VEGF-induced syndrome resembles peliosis hepatis, a rare human condition that is encountered in the setting of advanced malignancies, high-dose androgen therapy, and Bartonella henselae infection. " 07/01/2002 - "These features support the concept that peliosis hepatis can be induced by a circulating tumor-derived endothelial growth factor such as vascular endothelial growth factor."

Therapies and Procedures

1.	Aftercare (After-Treatment) 06/01/2000 - "Peliosis hepatis after treatment with 2-chloro-3'-deoxyadenosine." 03/25/1978 - "[Peliosis hepatis after treatment with androgens. " 05/01/1995 - "We report a case of regressive peliosis hepatis, which occurred in a 55 year-old woman with diffuse intestinal lymphomatous polyposis in remission after treatment with chemotherapy and radiotherapy, and which was cleared after one month treatment with erythromycin. " 10/25/1993 - "Investigations of the liver indicated peliosis hepatis after treatment with 3 or 10 micrograms/kg. Activities of microsomal enzymes (ethoxyresorufin O-deethylase, ethoxycoumarin O-deethylase, aryl hydrocarbon hydroxylase, UDP-glucuronyltransferase) investigated in liver, lung and kidney were dose-dependently elevated after 13 weeks of treatment. "
2.	Radiotherapy 05/01/1995 - "We report a case of regressive peliosis hepatis, which occurred in a 55 year-old woman with diffuse intestinal lymphomatous polyposis in remission after treatment with chemotherapy and radiotherapy, and which was cleared after one month treatment with erythromycin. "
3.	Drug Therapy (Chemotherapy) 05/01/1995 - "We report a case of regressive peliosis hepatis, which occurred in a 55 year-old woman with diffuse intestinal lymphomatous polyposis in remission after treatment with chemotherapy and radiotherapy, and which was cleared after one month treatment with erythromycin. "
4.	Kidney Transplantation 01/01/1994 - "Laparoscopic study of peliosis hepatis and nodular transformation of the liver before and after renal transplantation: natural history and aetiology in follow-up cases." 01/01/1994 - "Although peliosis hepatis and nodular transformation of the liver can occur after renal transplantation, their prevalence has not been well defined. " 07/01/1984 - "Peliosis hepatis after renal transplantation." 08/01/1978 - "Peliosis hepatis, an uncommon liver lesion characterised by blood-filled cavities bordered by hepatocytic plates, was found in 12 patients three to 17 months after renal transplantation. " 03/07/2014 - "Peliosis hepatis complicated by portal hypertension following renal transplantation."
5.	Transplants (Transplant) 01/01/1984 - "[Developmental aspects of the lesions in peliosis hepatis in renal transplant patients]." 08/01/1978 - "Peliosis hepatis in recipients of renal transplants." 04/15/1998 - "Herein, we report the first case of bacillary peliosis hepatis due to systemic Bartonella henselae infection in a patient after kidney transplant. " 10/01/1987 - "Peliosis hepatis and nodular regenerative hyperplasia of the liver in renal transplants. " 06/01/2012 - "TJLB is indicated for patients with coagulopathy, ascites, peliosis hepatis, morbid obesity, liver transplant, or in patients undergoing a transjugular intrahepatic portosystemic shunt procedure. "